While postmortem AD pathology (amyloid burden and tau density) does not seem To be affected in older adults treated with metformin for An average of 8 years when compared with non-users, as revealed in a cross-sectional study [351], neuroimaging findings in patients with MCI and diabetes are more mixed. This evidence concerns the gene MAPT and Alzheimer disease.